Zhejiang Cancer Hospital

This clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…

This early-phase trial tests whether umbilical cord blood cells can safely help people with chronic radiation enteritis, a painful gut condition caused by cancer radiation therapy. Ten adults who have had pelvic or abdominal radiation will receive three weekly infusions of these …

This early-stage trial tests whether umbilical cord blood cells can safely treat lung damage caused by radiation therapy for cancer. Ten adults who have not improved with standard care will receive three weekly infusions of these cells. The main goal is to check safety and see if…

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…

This study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …

This observational study will follow 300 premenopausal women with HR-positive early breast cancer who are already receiving ovarian function suppression (OFS) therapy as part of their routine care. Researchers want to see how many patients stop OFS within two years and why, and w…